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Background: Progerin is a mutant form of lamin A responsible for Hutchinson-Gilford progeria 
syndrome (HGPS), a premature aging disorder characterized by excessive atherosclerosis and 
vascular calcification that leads to premature death, predominantly from myocardial infarction or 
stroke. The goal of this study was to investigate mechanisms causing excessive vascular calcification 
in HGPS. 
Methods and Results: We performed expression and functional studies in wild-type mice and 
knock-in LmnaG609G/+ mice expressing progerin, which mimic the main clinical manifestations of 
HGPS. LmnaG609G/+ mice showed excessive aortic calcification, and primary aortic vascular smooth 
muscle cells (VSMCs) from these progeroid animals have an impaired capacity to inhibit vascular 
calcification. This defect in progerin-expressing VSMCs is associated with increased tissue 
expression and activity of tissue-nonspecific alkaline phosphatase (TNAP) and mitochondrial 
dysfunction leading to reduced ATP synthesis. Accordingly, LmnaG609G/+ VSMCs are defective for 
the production and extracellular accumulation of pyrophosphate, a major inhibitor of vascular 
calcification. We also found increased alkaline phosphatase activity and reduced ATP and 
pyrophosphate levels in plasma of LmnaG609G/+ mice without changes in phosphorus and calcium. 
Treatment with pyrophosphate inhibited vascular calcification in progeroid mice. 
Conclusions: Excessive vascular calcification in LmnaG609G mice is caused by reduced extracellular 
accumulation of pyrophosphate resulting from increased TNAP activity and diminished ATP 
availability caused by mitochondrial dysfunction in VSMCs. Excessive calcification is ameliorated 
upon pyrophosphate treatment. These findings reveal a previously undefined pathogenic process in 
HGPS that may also contribute to vascular calcification in normal aging, since progerin progressively 
accumulates in the vascular tissue of non-HGPS individuals.  




Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare sporadic genetic disorder that is 
characterized by accelerated cardiovascular disease and premature aging.1, 2 Most (>90%) HGPS 
patients carry a non-inherited autosomal dominant de novo heterozygous mutation at codon 608 of 
the LMNA gene (c.1824C>T: GGC>GGT; p.G608G). This mutation activates a cryptic splice donor 
site, causing the synthesis of progerin. 1, 2 Expression of this lamin A mutant disrupts the nuclear 
membrane architecture and causes multiple cellular alterations, including impaired DNA repair 
capacity and abnormal higher-order chromatin organization, gene transcription and signal 
transduction.3, 4 HGPS patients exhibit accelerated atherosclerosis and die at a mean age of 13.4 years 
(range, 8-21 years) predominantly from myocardial infarction or stroke.5-7 Additional clinical HGPS 
manifestations include dermal and bone abnormalities, alopecia and joint contractures.5, 8-16 
Moreover, the aortas and aortic valves of HGPS patients are excessively calcified,10-12 and arteries 
from old transgenic mice carrying a human bacterial artificial chromosome that harbors the common 
HGPS mutation accumulate calcium deposits that are absent in age-matched controls.17 However, the 
mechanisms underlying excessive vascular calcification in HGPS remain unexplored. 
Vascular calcification typically manifests as calcium-phosphate deposition (CPD) in distinct 
layers of the aortic wall.18, 19 Calcium-phosphate deposits are composed of several members of the 
calcium orthophosphate family, including hydroxyapatite, octocalcium phosphate and amorphous 
calcium phosphate.20 Medial calcification occurs within the elastin region of arteries and is almost 
exclusively associated with vascular smooth muscle cells (VSMCs). Elevated serum phosphorus (in 
the form of inorganic phosphate) is a major risk factor for vascular calcification.21, 22 In vitro and in 
vivo studies have shown that elevated inorganic phosphate concentration in VSMCs triggers a 
transition to a bone-forming phenotype.18, 19 This transition results in over-expression of 
osteochondrogenic markers, such as the transcription factor Runx2 (also named Cbfa1), which 
induces the expression of major bone matrix components.18, 19  
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Extracellular pyrophosphate (ePPi) directly blocks CPD in vitro and in vivo and is therefore a 
major endogenous inhibitor of vascular calcification.23-26 Degradation of ePPi is catalyzed by tissue-
nonspecific alkaline phosphatase (TNAP), which hydrolyzes PPi to inorganic phosphate. Importantly, 
calcification in ex vivo cultured rat aorta is induced by alkaline phosphatase and is prevented by 
TNAP inhibitors.26, 27 TNAP is moreover up-regulated in the aortas of uremic rats, resulting in 
increased hydrolysis of ePPi and vascular calcification.28 The main enzyme involved in ePPi 
synthesis, both in aorta and in cultured VSMCs, is the ectoenzyme nucleotide 
pyrophosphatase/phosphodiesterase-1 (eNPP1).26, 29 Lack of eNPP1 leads to extensive and fatal 
arterial calcification in children and mice.30, 31 The substrate for eNPP1 is ATP, which accumulates in 
the extracellular matrix via the action of several transporters,32 such as the multiple-pass 
transmembrane protein ANK.33 
To define the molecular mechanisms that lead to vascular calcification in HGPS, we analyzed 
LmnaG609G knock-in mice, which express progerin as a consequence of aberrant splicing resulting 
from the LMNA c.1827C>T (p.G609G) mutation, equivalent to the human mutation c.1824C>T 
(p.G608G).34 This new mouse model of progeria mimics the main clinical manifestations of human 
HGPS, including cardiovascular aberrations and premature death.34 Our studies reveal profound 
alterations in ePPi homeostasis caused by progerin expression that exacerbate vascular calcification, 




Mice. Male LmnaG609G/+, LmnaG609G/G609G and wild-type littermates were used.34 Animal studies were 
approved by the local ethics committee and conformed to Directive 2010/63EU and 
Recommendation 2007/526/EC regarding the protection of animals used for experimental and other 
scientific purposes, enforced in Spanish law under Real Decreto 1201/2005. 
Cell culture. VSMCs were prepared from thoracic aortas of 30-32-week-old mice as described 
previously.35 Cells were grown in minimal essential medium (MEM) containing 1 mM L-glutamine, 
100 IU/ml penicillin, 100 µg/ml streptomycin and 10% fetal bovine serum (FBS) at 37ºC in a 
humidified atmosphere at 5% CO2. VSMCs were used at passages 5-10. Cells were grown to 
confluence and used after an overnight quiescence step (0.1% FBS). Calcification assays were 
performed on cells incubated for 7 days in MEM supplemented with 0.1% FBS and 2 mmol/L Pi as 
described previously.35, 36 For phosphatase activity studies and ATP and PPi measurements, VSMCs 
were incubated in medium without Phenol Red.  
Quantification of calcium deposition. Aortic arch and thoracic aorta from wild-type and 
LmnaG609G/+ mice (n=5 per genotype) were included in OCT (Sakura, Netherlands), and 4-µm cross-
sections were cut with a cryostat (Leica CM1950, Barcelona, Spain). Calcification in aortic tissue 
was revealed by Alizarin red staining as described.35, 36 To quantify calcium deposits, 2-4 aortic 
cross-sections of each mouse were analyzed with ImageJ (http://imagej.nih.gov/ij/docs/guide). 
To quantify calcium content in VSMCs, cells were treated with 0.6 HCl overnight at 4ºC and 
analyzed with a colorimetric QuantiChrom calcium assay kit (BioAssay Systems, Hayward, 
California).  
Pyrophosphate treatment in vivo. PPi (Sigma, S6422) was dissolved in sterile saline (B.Braun 
Medical SA, Barcelona, Spain). 10-week-old LmnaG609G/G609G mice were treated with PPi for 9 weeks 
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(daily intraperitoneal injection, 100 mg/Kg/day) and the control group received saline (n=5 mice in 
each group). Quantification of aortic calcification was performed as indicated above.  
Quantitative real-time PCR (qPCR). Total RNA was isolated from mouse aorta or VSMCs using 
Qiazol lysis reagent (Qiagen, Madrid, Spain). After DNase treatament, 2 µg RNA was reverse 
transcribed using the High capacity cDNA reverse transcription kit (Applied Biosystems, Madrid, 
Spain). qPCR was performed using Power SYBR Green in 384-well clear optical reaction plates on 
an ABI PRISM 7900HT Sequence Detection System following the manufacturer’s instructions for 
calibrator normalization (Applied Biosystems). All reactions were carried out in triplicate. The 
primers used for amplification were as follows: 1) BMP-2 (NM_007553): 5`-
CACCGTGCGCAGCTTCCA-3` (forward), 5`-CCGGGCCGTTTTCCCACTCA-3` (reverse); 2) 
Runx2 (NM_001146038.1): 5`-CAGATCCCAGGCAGGCACAGTC-3` (forward), 5`-
ACAGCGGCGTGGTGGAGTG-3` (reverse); 3) eNPP1 (NM_008813): 5`-
GGATTGTGCCAATAAGGACT-3` (forward), 5`- CAAGAACTGTTGCTGCTGGAG -3` 
(reverse); 4) TNAP (NM_007431): 5`-CTATGTCTGGAACCGCACTGA-3` (forward), 5`- 
AGCCTTTGAGGTTTTTGGTCA -3` (reverse); 5) Pit1 (NM_015747): 5`- 
CTGCTTCACGAGTGGGTAGAG-3` (forward), 5`- TGTAAACTACGGCACGGAAAC-3` 
(reverse); 6) Pit2 (NM_011394): 5`-CTCTACAACGAGACCGTGGAA-3` (forward), 5`- 
CATGAAGCCAGAAAGAAGTGG -3` (reverse); 7) ANK (NM_020332): 5`-
CATCCCCATCCTGTCTCTGTA-3` (forward), 5`- ACACGAAGAGGTTGACAATGG -3` 
(reverse); 8) eNTPD1 (NM_009848): 5`-AGCCTCCACACAGATCACCTT-3` (forward), 5`- 
GCCACCACTTGAAACCTGAAT -3` (reverse); 9) Fetuin A (NM_013465): 5`-
ATCGACAAAGTCAAGGTGTGG-3` (forward), 5`- CAACTTACGAACGTCCTCTGC -3` 
(reverse); 10) Matrix Gla-protein (NM_008597): 5`-AGGAGAAATGCCAACACCTTT-3` 
(forward), 5`- ACGAAACTCCACAACCAAATG -3` (reverse). Expression was quantified by the 
comparative CT method, with correction for the expression of the endogenous control gene acidic 
ribosomal phosphoprotein P0 (RPLP0, accession number NM_007475). 
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Immunoblots and inmunohistochemistry. VSMC lysates were prepared in lysis buffer (0.1% SDS, 
25 mM Tris-HCl pH 7.4 and protease inhibitors) and 30-50 µg protein were separated by SDS-PAGE 
and blotted to PVDF membrane as previously described.35 The following primary antibodies were 
used: rabbit monoclonal anti-eNTPD1 (1/5000, ab108248, Abcam, Cambridge, UK), rabbit 
polyclonal anti-TNAP (1µg/ml, ab65834, Abcam),  rabbit polyclonal anti-GFP (1/2500, ab6556, 
Abcam) and mouse monoclonal anti-α-Tubulin (1/5000, sc-8035, Santa Cruz biotechnology, USA). 
After incubation with appropriate secondary antibodies, blots were revealed using the ECL system 
(Millipore, Billerica, MA, USA). Mouse aortas were immunohistochemically stained with a rabbit 
polyclonal antibody to Runx2 (1/500, ab102711, Abcam). 
Phosphatase activity and ATP hydrolysis assays. Phosphatase activity in VSMCs or plasma was 
measured using the pNPP phosphatase assay kit and the Quantichrom alkaline phosphatase assay kit 
(BioAssay Systems), respectively. ATP hydrolysis assays in VSMCs cultures were performed as 
previously described.26 Briefly, cells were seeded in 12-well plates and incubated for the indicated 
times with 1µM ATP and 1 μCi/mL [γ32P]ATP radiotracer (Perkin Elmer, Madrid, Spain). ATP, 
inorganic phosphate and PPi in the culture medium were then separated by chromatography on PEI-
cellulose plates and were developed with 650 mM KH2PO4 pH 3. After autoradiography, spots were 
excised and counted by liquid scintillation.  
ATP and pyrophosphate quantification. ePPi was measured using an enzyme-linked 
bioluminescence assay in which PPi reacts with adenosine 5’-phosphosulfate (A5508, Sigma) in the 
presence of ATP-sulfurylase (A8957, Sigma) to generate ATP 29. For each sample, the blank 
(reaction without ATP-sulfurylase) was subtracted to obtain the true PPi amount. ATP was measured 
by a coupled luciferin/luciferase reaction using an ATP determination kit (Invitrogen, Paisley, UK).  
Generation of retroviral vectors and stable cell lines. Wild-type pre-lamin A and progerin cDNAs 
were PCR amplified using as template a previously published construct37 or Addgene plasmid 
#17663, respectively. Amplicons were inserted into pECFP vector (Clontech). Cyan fluorescent 
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protein (CFP)-pre-lamin A and progerin-CFP were then subcloned into pMSCVpuro retroviral vector 
(Clontech, Moustain View, CA) after digestion with XhoI/EcoRI to respectively generate 
pMSCVpuro/CFP-pre-lamin A (which is post-translationaly modified to generate mature lamin A) 
and pMSCVpuro/Progerin-CFP. Correct cloning of both plasmids was verified by DNA sequencing. 
The precise primer sequences and cloning strategies are available upon request. To generate 
retroviral stocks, 5×106 HEK-293T cells were plated in 100 mm dishes. After 12 h, cells were 
transfected (Lipofectamine 2000; Invitrogen) with 10 μg pCL-Ecotropic vector and 10 μg of the 
desired plasmid (pMSCVpuro/CFP-pre-lamin A or pMSCVpuro/Progerin-CFP). Two days post-
transfection, supernatants were harvested and filtered to obtain retroviral stocks. Primary VSMCs 
prepared from the aortas of 8-week-old C57BL/6J mice were incubated for 4 hr at 37°C with 
retroviral supernatant supplemented with 4 μg/mL polybrene. After 3 rounds of infection, cells were 
washed once with PBS and cultured in growth medium in the presence of 1 µg/mL puromycin until 
complete selection was achieved (passages 6-7). The subpopulations of cells expressing the CFP 
recombinant proteins were obtained using a fluorescence-activated cell sorter (FACSAria III cell 
sorter, BD Bioscience, San José, CA, EE.UU.).  
Mitochondrial assays. Mitochondrial ATP synthesis in digitonin-permeabilized VSMCs (2x106 
cells) was measured by kinetic luminescence assay. Cytochrome c oxidase (COX) and citrate 
synthase (CS) enzymatic activities were measured in cell lysates (30–50 µg protein) as described,38 
and expressed as international units (IU) per mg protein. COX activity was normalized to CS, a 
Krebs cycle enzyme used as an index of mitochondrial mass.  
Statistical analysis. Results are expressed as mean±SEM. For the studies shown in Figure 1, 2, 3, 4 
and 5A, results were analyzed using unpaired Student’s t-test with Welch’s correction for two 
samples with possibly unequal variance. The results in Figure 5B were analyzed using paired 





Vascular smooth muscle calcification is increased in progeroid LmnaG609G/+ mice. HGPS patients 
carry the LMNA mutation in heterozygosis and express both lamin A and progerin.1, 2 We therefore 
performed studies with heterozygous LmnaG609G/+ mice that also express lamin A and progerin and 
have a significantly shortened lifespan (average 34 weeks, compared with more than 2 years for wild-
type controls) 34. We used 30-32-week-old LmnaG609G/+ mice. Gross examination of Alizarin Red-
stained vessels revealed prominent medial calcification in aortic arch and thoracic aorta of 
LmnaG609G/+ compared with wild-type mice, and computer-assisted planimetric analysis showed 
statistically significant differences between genotypes (Fig.1A). Consistent with these findings, 
qPCR revealed that calcified aortas from LmnaG609G/+ mice have high mRNA levels of BMP-2 and 
Runx2, two osteogenic markers expressed during vascular calcification, but no changes were 
observed in the anti-calcification agents matrix Gla-protein (MGP) and fetuin A (Fig.1B,C). 
Immunohistochemical analysis confirmed the increase in Runx2 expression in LmnaG609G/+ aortas 
compared with aortas from wild-type mice (Fig.1D). 
We next studied primary cultures of VSMCs isolated from aortic tissue of wild-type and 
LmnaG609G/+ mice. Previous in vitro studies showed that CPD is more prominent with lysed VSMCs 
than with live cells, suggesting that VSMCs synthesize CPD inhibitors.25, 35, 36 We therefore 
compared the CPD-inhibitory capacity of wild-type and LmnaG609G/+ VSMCs. Cells were incubated 
for 7 days in calcifying medium, and the difference in CPD between lysed and live cells (ΔCa2+) was 
calculated. LmnaG609G/+ VSMCs showed a significantly lower capacity to inhibit calcium deposition 
than equivalent numbers of control cells, after normalization for protein concentration (Fig 1E).  
LmnaG609G/+ VSMCs have an impaired capacity to synthesize extracellular pyrophosphate. 
Since excessive calcification in LmnaG609G/+ aorta was not associated with reduced expression of 
MGP and fetuin A (Fig.1B), we quantified in VSMC-conditioned culture medium the accumulation 
of ePPi, the major endogenous inhibitor of vascular calcification.21, 23-26 After 2 days in culture, ePPi 
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levels were 3.8-fold lower in LmnaG609G/+ VSMCs compared with wild-type controls (Fig.2A). RT-
PCR analysis of enzymes and transporters involved in ePPi metabolism demonstrated significantly 
higher expression of TNAP, Apyrase1/eNTPD1 and the phosphate transporter Pit2 in LmnaG609G/+ 
compared with wild-type VSMCs, whereas eNPP1, ANK and Pit1 were unaffected (Fig.2B). Western 
blot analysis confirmed the increase in the ectoenzymes TNAP and eNTPD1 in LmnaG609G/+ VSMCs 
(Fig.2C). Moreover, phosphatase activity was 2-fold higher in LmnaG609G/+ VSMCs (Fig.2D). 
Given these findings, we next investigated the capacity of LmnaG609G/+ VSMCs to synthesize 
PPi using ATP as substrate. Cells were incubated for different times with 1 µM ATP and [γ32P]-ATP 
radiotracer, and radioactive ATP, PPi and inorganic phosphate (Pi) were quantified in the culture 
medium after separation by thin-layer chromatography (Fig.2E). Wild-type and LmnaG609G/+ VSMCs 
showed indistinguishable rates of ATP hydrolysis, with approximately 98% of ATP being hydrolyzed 
after 80 minutes (Fig.2E). However, the amount of ePPi produced was only 28% in LmnaG609G/+ 
VSMCs, compared with 47% in wild-type cells, and the amount of Pi produced was 68% in 
LmnaG609G/+ VSMCs compared with 49% in wild-type cells (Fig.2E). Accordingly, the Pi:PPi ratio 
increased from 1:1 in wild-type VSMCs to 2.4:1 in LmnaG609G/+ VSMCs. 
VSMCs expressing progerin have impaired ATP synthesis and mitochondrial function. 
Extracellular ATP hydrolysis is the major source of ePPi in aorta and in VSMCs.26 We therefore 
analyzed intracellular ATP levels and extracellular ATP accumulation in wild-type and LmnaG609G/+ 
VSMCs. LmnaG609G/+ VSMCs showed significantly lower levels of extracellular ATP (Fig.3A) and 
intracellular ATP (Fig.3B). LmnaG609G/+ VSMCs also exhibited lower mitochondrial ATP production 
(Fig.3C). This was associated with a significantly lower COX/CS ratio (Fig.3D), indicating impaired 
activity of COX, an essential component of the mitochondrial electron transport chain.  
To assess whether the alterations observed in LmnaG609G/+ VSMCs are a direct consequence of 
progerin expression, we performed retrovirus-mediated gain-of-function experiments. Western blot 
analysis demonstrated CFP-lamin A and progerin-CFP expression in primary mouse VSMCs infected 
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with retrovirus encoding these proteins (Fig.4A). In agreement with many previous studies in 
different cell types, infected VSMCs expressed CFP-lamin A predominantly in the perinuclear rim, 
whereas progerin-CFP was found in both the perinuclear rim and in nucleoplasmic aggregates 
(Fig.4B). Compared with VSMCs expressing CFP-lamin A, forced progerin expression in VSMCs 
led to increased TNAP and Apyrase1/eNTPD1 mRNA steady-state levels without affecting the 
expression of others enzymes and transporters involved in ePPi metabolism (Fig.4C). Western blot 
analysis confirmed the increase in TNAP and eNTPD1 in LmnaG609G/+ VSMCs overexpressing 
progerin (Fig.4D). Consistent with the results in primary LmnaG609G/+ VSMCs, we also found 
significant reductions in extracellular and intracellular ATP concentration, mitochondrial ATP 
synthesis, COX/CS ratio, and ePPi levels in progerin-CFP-overexpressing VSMCs compared with 
CFP-lamin A-expressing controls  (Fig.4E).   
Progeroid mice have affected plasma parameters involved in vascular calcification. Since 
hyperphosphatemia and hypercalcemia lead to CPD,19 we quantified inorganic phosphate and 
calcium in plasma from wild-type and LmnaG609G/+ mice (Fig.5A). These parameters were similar in 
both genotypes (phosphorus: 8.2±0.2 in wild-type versus 7.7±0.3 mg/dl in LmnaG609G/+ ; calcium: 
14.4±0.3 in wild-type versus 14.8±0.3 mg/dl in LmnaG609G/+ ; p>0.05). However, the plasma of 
LmnaG609G/+ mice exhibited higher alkaline phosphatase activity (29.5% higher) and lower 
concentrations of ATP (8-fold) and ePPi (9-fold) (Fig.5A).  
Pyrophosphate treatment inhibits aortic calcification in progeroid mice. Recent studies showed 
that injection of exogenous PPi prevents uremic vascular calcification in rats and mice.24, 39 We 
therefore investigated the effect of PPi injection on vascular calcification in progeroid mice. For these 
studies, we used homozygous LmnaG609G/G609G mice, which are more severely affected than 
heterozygous LmnaG609G/+ mice, with an average lifespan of only 103 days.34 Ten-week-old 
homozygous LmnaG609G/G609G males received daily intraperitoneal injections of saline (control group) 
or PPi over 9 weeks (100 mgkg-1day-1, n=5 mice in each group). We did not observe differences in 
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body weight and mortality during follow-up, but post-mortem analysis demonstrated a statistically-
significant reduction in aortic calcification in PPi-treated mice compared with controls, as revealed 





The aim of the present study was to identify molecular mechanisms that contribute to excessive 
vascular calcification in HGPS, a rare premature aging disorder caused by abnormal expression of 
progerin.1, 2 Available evidence indicates that vascular calcification involves both passive and active 
processes18, 19, 25 (Fig.6). CPD in the aortic wall and in in vitro models is the main feature of vascular 
calcification. At physiological serum concentrations of calcium and phosphate, CPD is a passive 
process that does not require cellular activity.20, 25, 36, 40 Active processes involved in vascular 
calcification include reduced capacity of VSMCs to synthesize and secrete calcification inhibitors, 
such as MGP, fetuin A and ePPi, and the transition of VSMCs to a bone-forming phenotype, a 
process that is enhanced via CDP-dependent overexpression of osteochondrogenic factors, including 
Runx2.18, 19, 36, 41 Pi is essential for the synthesis of ATP, the main source of ePPi.26 It has thus been 
proposed that defective ATP production by VSMCs may impair the synthesis of CPD inhibitors.42 
Previous studies revealed that old transgenic mice carrying the common HGPS mutation exhibit a 
vascular calcification not seen in age-matched controls.17 However, the mechanisms by which 
progerin exhacerbates vascular calcification remain unknown. Here, we have shown that progerin 
expression in LmnaG609G/+ mice causes excessive vascular calcification associated with VSMC 
abnormalities that lead to impaired mitochondrial function and ATP production and reduced PPi 
synthesis (Fig.6), without affecting expression of the anti-calcification agents MGP and fetuin A. The 
causal relationship between progerin-induced low plasma ePPi and vascular calcification is 
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reinforced by our observation that aortic calcification in progeroid mice is reduced by treatment with 
PPi. It is noteworthy that physiological aging of non-HGPS individuals is associated with 
mitochondrial dysfunction43, 44 and with a progressive accumulation of progerin in several tissues,45-48 
including vascular tissue.6 Thus our findings might be relevant to vascular calcification not only in 
HGPS patients but also in the elderly.  
Because HGPS patients carry the LMNA mutation in heterozygosis,1, 2 we studied heterozygous 
LmnaG609G/+ mice that express both lamin A and progerin.34 We found excessive aortic calcification 
in progeroid LmnaG609G/+ mice, which was associated with increased aortic expression of Runx2 and 
Bmp-2, two osteochondrogenic markers expressed in VSMCs during calcification in vivo and in 
vitro19 that are induced by CPD.36, 41 Importantly, VSMCs from LmnaG609G/+ mice also exhibited an 
impaired capacity to inhibit CPD in vitro, which might explain the excessive medial calcification and 
the consequent overexpression of osteogenic markers in the aorta of LmnaG609G/+ mice. To investigate 
the molecular mechanisms through which progerin triggers vascular calcification, we focused on the 
enzymes and transporters involved in ePPi homeostasis, a complex process that involves a balance 
between synthesis and degradation. Our results provide evidence that excessive vascular calcification 
in LmnaG609G/+ mice is the consequence of alterations in VSMCs, including impaired synthesis of 
PPi, which leads to reduced accumulation of ePPi (Fig.6). Additional factors contributing to 
progerin-dependent reduction in ePPi levels include the upregulation of the ectoenzymes TNAP (the 
main enzyme involved in ePPi hydrolysis) and apyrase1/eNTPD1 (an enzyme that hydrolyzes ATP to 
release Pi), and low synthesis of ATP (the major substrate for ePPi synthesis). Our studies suggest 
that impaired ATP synthesis in LmnaG609G/+ VSMCs is due to mitochondrial dysfunction associated 
with reduced complex IV COX activity. Importantly, retrovirus-mediated overexpression of progerin 
in wild-type VSMCs recapitulates the alterations observed in VSMCs isolated from LmnaG609G/+ 
mice, including increased expression of TNAP and apyrase1/eNTPD1, reduced extracellular and 
intracellular ATP, diminished mitochondrial COX-CS ratio and ATP synthesis, and lower ePPi 
accumulation. A-type lamins have been linked to the regulation of multiple cellular processes (e.g., 
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higher-order chromatin organization, DNA repair and replication, signal transduction, gene 
transcription, and cell proliferation, differentiation and migration), many of which are altered on 
progerin expression.3, 4 Therefore additional studies are required to refine our understanding of the 
molecular mechanisms through which progerin expression alters VSMC behavior to promote 
calcification.  
Hyperphosphatemia causes vascular calcification, thus underscoring the importance of Pi 
homeostasis in CPD. However, in a study of 15 HGPS patients with a wide age range of 1.6-17.8 
years, Merideth et al.5 reported a plasma phosphate concentration of 5.5±0.2 mg/dl, which is within 
the normal range in humans (2.7-5.5 mg/dl). We also found that LmnaG609G/+ mice have plasma 
phosphorus concentrations in the normal range, undistinguishable from their wild-type littermates 
(8 mg/dl; normal range in mice: 5.7-9.2 mg/dl). Likewise, plasma calcium levels were normal in 
progeroid mice. These results indicate that hyperphosphatemia and hypercalcemia do not contribute 
to excessive vascular calcification in LmnaG609G/+ mice, thus emphasizing the importance of reduced 
synthesis of ePPi by VSMCs as a key mechanism triggering excessive vascular calcification in 
HGPS. Although plasma phosphate levels are normal in LmnaG609G/+ mice, increased accumulation of 
Pi in the tunica media may contribute to CPD in these animals, because the present results in primary 
VSMCs from LmnaG609G/+ mice show augmented Pi production from ATP hydrolysis accompanied 
by a high Pi:PPi ratio of 2.4:1, compared with 1:1 in wild-type cells (Fig. 2E). The defect in ePPi 
production by progerin-expressing VSMCs is unlikely to be counterbalanced systemically, because 
PPi concentration in plasma from LmnaG609G/+ mice was also significantly reduced compared with 
wild-type controls, probably as a result of lower ATP concentration and higher alkaline phosphatase 
activity in plasma. Our observation that PPi treatment inhibits aortic calcification in progeroid mice 
underscores the role of defective ePPi homeostasis as a key factor underlying excessive vascular 
calcification in HGPS. We did not observe changes in body weight or mortality upon PPi treatment. 
However, it is important to note that these studies were performed in homozygous LmnaG609G/G609G 
mice that have an average life span of only 15 weeks,34 and treatment was started at 10 weeks of age, 
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when the animals already exhibit severe symptoms.34 HGPS patients carry the LMNA mutation in 
heterozygosis,1, 2 and therefore future studies are warranted in very young heterozygous LmnaG609G/+ 
mice (1-2-weeks-old) to ascertain whether chronic treatment with PPi starting early in life, when 
symptoms are absent or very mild, can not only inhibit vascular calcification but also improve the 
general health and lifespan of progeroid mice. 
Since imbalances in the degradation and synthesis of ePPi have been shown to lead to 
pathologic calcification of articular cartilage,49 the systemic defect in circulating PPi associated with 
progerin expression might promote not only excessive vascular calcification but also the appearance 
of joint contractures, a characteristic of both HGPS patients5 and LmnaG609G mice.34 Treatment with 
PPi might thus ameliorate both vascular calcification and joint contractures. It is noteworthy that 
combined treatment with statins and bisphosphonates (nonhydrolyzable pyrophosphate analogues) 
significantly extends the average lifespan of progeroid Zmpste24-/- mice, another model of premature 
aging caused by abnormal accumulation of prelamin A.50 Based on these findings, ongoing clinical 
trials are assessing the efficacy of statin plus bisphosphonate (pravastatin plus zoledronate) with or 
without farnesyl transferase inhibitor (http://www.progeriaresearch.org/clinical_trial.html). However, 
although treatment with bisphosphonates decreases aortic calcification, animal studies have identified 
adverse effects of these compounds in bone.51, 52 Moreover, bisphosphonates have been shown to 
induce the rupture of atherosclerotic plaques in apolipoprotein E-null mice.53 In contrast, recent 
studies have shown that exogenous PPi injected daily into uremic rats and mice reduces the calcium 
content in calcified aortas without producing adverse effects on bone.24, 39 Moreover, TNAP and 
PHOSPHO1 inhibitors can inhibit vascular calcification.27, 54 Future studies in HGPS mouse models 
are thus warranted to investigate whether treatment with PPi in combination with TNAP or 






Progerin, a mutant form of lamin A, is responsible for Hutchinson-Gilford progeria syndrome 
(HGPS), a rare premature aging disorder featuring excessive vascular calcification (VC). Calcium 
dysfunction is under-studied in HGPS. Here, we show that progerin-expressing heterozygous 
LmnaG609G/+ mice, which mimic the main clinical manifestations of HGPS, develop excessive VC. 
Moreover, primary vascular smooth muscle cells (VSMCs) from LmnaG609G/+ mice exhibit above 
normal tissue-nonspecific alkaline phosphatase (TNAP) and apyrase 1/eNTPD1, and below normal 
mitochondrial ATP synthesis and extracellular ATP accumulation. Accordingly, LmnaG609G/+ 
VSMCs show defective production and extracellular accumulation of pyrophosphate, a major 
inhibitor of VC. We also found elevated alkaline phosphatase activity and low ATP and 
pyrophosphate levels in plasma of LmnaG609G/+ mice. Administration of pyrophosphate to severely 
ill progeroid LmnaG609G/G609G mice carrying the LMNA mutation in homozygosis inhibited VC but 
did not increase body weight or improve mortality. Because HGPS patients carry the LMNA 
mutation in heterozygosis, future studies are warranted in heterozygous LmnaG609G/+ mice to 
ascertain whether chronic treatment with pyrophosphate starting early in life can not only inhibit 
VC but also improve general health and lifespan. It will also be of interest to determine whether 
anti-calcification treatment with pyrophosphate and TNAP or PHOSPHO1 inhibitors, in 
combination with the farnesyl transferase inhibitors and statins currently under evaluation in HGPS 
clinical trials, is more beneficial than current strategies. Since progerin progressively accumulates in 
the vascular tissue of non-HGPS individuals, these studies should shed light on VC associated with 
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Figure 1. Excessive calcification in aorta and vascular smooth muscle cells from LmnaG609G/+ 
mice. Thirty- to 32-week-old male LmnaG609G/+ and wild-type mice and derived VSMCs were 
analyzed. (A) Representative images (x20) of Alizarin red staining and quantification of calcium 
deposition averaged from 2 to 4 aortic cross-sections for each mouse (n=5 mice per genotype). (B, C) 
qPCR analysis of the osteogenic markers BMP-2 and Runx2 and the calcification inhibitors matrix-
Gla protein (MGP) and fetuin A in aorta. Results are means±SEM and are normalized to the level in 
wild-type mice (n=5 per genotype). (D) Representative images of aortic cross-sections 
immunostained for Runx2 in wild-type and LmnaG609G/+ mice. The left panel shows the absence of 
staining in control experiments with secondary antibody but without anti-Runx2 antibody. (E) Live 
or lysed VSMCs were maintained in medium containing 1 mM Pi (non-calcifying media) or 2 mM Pi 
(pro-calcifying media) and calcium deposition was measured and normalized to protein content. The 
graph on the left shows the results of a representative experiment (means±SEM of six independent 
wells). The graph on the right shows the inhibition of calcium deposition in pro-calcifying media 
calculated as the difference between lysed and live cells for each genotype (means±SEM of three 
independent experiments performed with cells pooled from 10 mice per genotype). **: p<0.01, and #: 
p<0.0001 versus wild-type.   
 
Figure 2. VSMCs expressing progerin exhibit impaired ATP-dependent PPi synthesis and 
extracellular PPi accumulation. Primary VSMCs were obtained from wild-type and LmnaG609G/+ 
mice. (A) Quantification of ePPi accumulated over 2 days in culture. (B) qPCR analysis of 
ectoenzymes and transporters involved in vascular calcification. (C) Representative immunoblots and 
quantification of TNAP and eNTPD1 expression after normalization to α-tubulin (a.u., arbitrary 
units). (D) Alkaline phosphatase activity. Results in A-D are means±SEM of 3 independent 
experiments. (E) Cells were incubated with 1µM ATP plus 1 μCi/mL [γ32P]ATP. At time points 
23 
 
indicated in the graphs, inorganic phosphate (Pi), PPi and ATP in the culture medium were separated 
by thin-layer chromatography. A representative autoradiograph is shown in the left. The graphs show 
the quantification of ATP, Pi and PPi. Results are means±SEM of six wells. Similar results were 
obtained in two additional experiments. *: p<0.05, **: p<0.01 and #: p<0.0001 versus wild-type.  
 
Figure 3. VSMCs from progeroid LmnaG609G/+ mice have low ATP levels and mitochondrial 
dysfunction. Wild-type and LmnaG609G/+VSMCs were cultured to quantify the level of extracellular 
ATP (A), intracellular ATP (B), mitochondrial ATP synthesis (C), and the COX/CS activity ratio 
(D). Results are means±SEM of 12 determinations in two-three independent experiments. #: 
p<0.0001. 
 
Figure 4. Forced progerin expression in VSMCs induces alterations in extracellular PPi 
metabolism. Primary VSMCs obtained from wild-type mice were infected with retroviral vectors 
encoding CFP-Lamin A or progerin-CFP. (A) Western blot analysis using anti-GFP antibody. (B) 
Confocal microscopy to visualize CFP-lamin A and progerin-CFP. (C) qPCR of enzymes and 
transporters involved in ePPi metabolism. Results are normalized to the mRNA levels in CFP-lamin 
A controls. (D) Representative immunoblots and quantification of TNAP and eNTPD1 expression 
after normalization to α-tubulin (a.u., arbitrary units). (E) Determination of extracellular and 
intracellular ATP, mitochondrial ATP synthesis, COX/CS ratio, and ePPi. Results are means±SEM 





Figure 5. PPi homeostasis in mouse plasma and treatment with exogenous PPi. (A) The 
indicated parameters were analyzed in plasma of 30-32-week-old male wild-type and LmnaG609G/+ 
mice. Results are means±SEM of 8-10 mice. (B) Ten-week-old male LmnaG609G/G609G mice received 
for 9 weeks a daily ip injection of saline or exogenous PPi (n=5 mice in each group). Images show 
representative examples of Alizarin red-stained aortic tissue (boxed areas are shown at higher 
magnification). The graph shows quantification of calcium deposition by planimetric analysis of 
stained cross-sections. ***: p<0.001 and #: p<0.0001.   
 
Figure 6. Proposed model of altered pyrophosphate homeostasis in HGPS. ePPi is a major 
inhibitor of calcium phosphate deposition that is synthesized from ATP by eNPP1 and degraded to Pi 
by TNAP. Pit1 and Pit2 mediate the cellular uptake of Pi, which is essential for ATP synthesis, 
mainly via mitochondrial oxidative phosphorylation. ATP is released to the extracellular matrix via 
the transporter ANK. Progerin expression in VSMCs augments TNAP and apyrase1/eNTPD1 and 
impairs mitochondrial function and ATP synthesis. These alterations lead to reduced extracellular 
concentrations of PPi and a high Pi:PPi ratio in the arterial wall. The plasma of LmnaG609G/+ mice 
exhibits normal phosphorus and calcium levels, but higher alkaline phosphatase activity (ALP) and 
lower concentrations of ATP and ePPi. These alterations in VSMCs and blood of progeroid 
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